Vector Science signs amended 10-year cGMP manufacturing deal with LyoGenesis
Reuters2026/08/17 11:45- Vector signed an amended, 10-year manufacturing and testing agreement with LyoGenesis, effective Aug. 13, 2026.
- Deal secures exclusive, U.S.-based cGMP capacity for Vector’s lyophilized peptide pharmaceutical products at LyoGenesis’ Mequon, Wisconsin facility.
- Verlytix will handle quality assurance inspections before batch release; product title transfers to Vector on delivery.
- Contract renews automatically in one-year terms after the initial decade; financial terms were not disclosed.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Serve Robotics (SERV.US) secures two major food delivery order channels after parting ways with Uber (UBER.US)! Commercialization of delivery robots expected to accelerate
Serve Robotics announced a new partnership with the U.S. online food delivery platform Grubhub and has expanded its collaboration with DoorDash, the largest food delivery app in the United States, to two additional cities.
Cerebras (CBRS.US) favored by Wedbush: Deeper collaboration with OpenAI, 750MW computing power order unlocks expansion potential
Wedbush Securities released a research report stating that after OpenAI disclosed its GPT-5.6 Sol’s Ultrafast mode will be powered by Cerebras, Wedbush believes that the existing partnership between the two parties is making “positive progress.”
Lavvi publishes 2Q26 results presentation factsheet
D.E. Shaw discloses net short position in Valneva shares
Crypto prices
More
